Provided by Tiger Fintech (Singapore) Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.28
+0.02001.59%
Post-market: 1.28-0.0007-0.05%19:50 EDT
Volume:1.44M
Turnover:1.82M
Market Cap:68.29M
PE:-1.92
High:1.32
Open:1.28
Low:1.21
Close:1.26
Loading ...

A Hewlett Packard exec sent a dramatic ‘KILL MIST’ email during its aggressive campaign to crush a rival, court docs revealed. Now HP wants to buy it for $14 billion

Fortune
·
31 Jan

BRIEF-Milestone Pharmaceuticals Provides 2025 Corporate Outlook And To Host Investor Event On Feb 25 In NYC

Reuters
·
28 Jan

Milestone Pharmaceuticals Inc: Pdufa Date of March 27, 2025 for Cardamyst™ (Etripamil) Nasal Spray

THOMSON REUTERS
·
28 Jan

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in Nyc

THOMSON REUTERS
·
28 Jan

Milestone Pharmaceuticals Inc: Plans to Initiate Phase 3 Study in Afib-Rvr in H1 2025

THOMSON REUTERS
·
28 Jan

Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
27 Jan

Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule

TIPRANKS
·
07 Jan

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Jan

Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire
·
25 Nov 2024

After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright

Zacks
·
19 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
13 Nov 2024

BRIEF-Milestone Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Million - SEC Filing

Reuters
·
13 Nov 2024

Milestone Pharmaceuticals Files for Mixed Shelf Offering of up to $250 Mln - SEC Filing

THOMSON REUTERS
·
13 Nov 2024

Milestone Pharmaceuticals Prepares for CARDAMYST Approval

TIPRANKS
·
13 Nov 2024

Milestone Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

Milestone Pharmaceuticals Q3 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate

Benzinga
·
12 Nov 2024

Milestone Pharmaceuticals: Q3 Earnings Snapshot

Associated Press Finance
·
12 Nov 2024

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

THOMSON REUTERS
·
12 Nov 2024

Milestone Pharmaceuticals: Milestone Is on Track to Initiate a Phase 3 Trial Evaluating Etripamil in Afib-Rvr in H1 2025

THOMSON REUTERS
·
12 Nov 2024

Milestone Pharmaceuticals Q3 Basic EPS USD -0.14

THOMSON REUTERS
·
12 Nov 2024